View Article

Abstract

The groundbreaking TEMPO 3:4 trial, which served as the basis for tolvaptan's approval, represented a revolution in the treatment of autosomal dominant polycystic kidney disease (ADPKD). Through this advancement, patient management for ADPKD has evolved from using broad strategies to stop the progression of chronic kidney disease to focusing on disease-specific mechanisms. Evidence-based strategies to start treatment only in patients with quickly worsening disease are essential, though, given the long-term nature of this medication and associated side effects. The European Renal Association (ERA) policy statement, released in 2016, was the first society-based guideline on the usage of tolvaptan and has been a popular resource for nephrologists when making decisions. Since then, there has been a significant accumulation of practical knowledge regarding the use of tolvaptan in ADPKD.

Keywords

ADPKD; polycystic kidney disease; position statement; tolvaptan; vasopressin V2 receptor antagonist

Reference

  1. Zilberberg MD, Exuzides A, Spalding J, et al. Epidemiology, clinical and economic outcomes of admission hyponatremia among hospitalized patients. Curr Med Res Opin. 2008;24(6):1601–1608.
  2. Verbalis JG, Goldsmith SR, Greenberg A, et al. Hyponatremia treatment guidelines 2007: Expert panel recommendations. Am J Med. 2007;120(11A):S1–S21. 
  3. Rockville, MD: Otsuka America Pharmaceutical, Inc.; May 2009. Samsca (tolvaptan), package insert. 
  4. Schrier RW, Gross P, Gheorghiade M, et al.for the SALT Investigators Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–2112.
  5. Gheorghiade M, Konstam MA, Burnett JC, et al.for the EVEREST Investigators Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA. 2007;297:1332–1343.
  6. Konstam MA, Gheorghiade M, Burnett JC, et al.for the EVEREST Investigators Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA. 2007;297:1319–1331.
  7. Schrier RW, Gross P, Gheorghiade M, et al.for the SALT Investigators Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–2112. 
  8. Gheorghiade M, Konstam MA, Burnett JC, et al.for the EVEREST Investigators Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA. 2007;297:1332–1343
  9. Konstam MA, Gheorghiade M, Burnett JC, et al.for the EVEREST Investigators Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA. 2007;297:1319–1331.
  10. Structure of Tolvaptan - https://web.chemdoodle.com/demos/iupac-naming#customise-template
  11. Indian Pharmacopoeia - 2022,  Ninth Edition, Volume – III, Page number: 3832, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chowdavaram, Guntur, Andhra Pradesh, India.

Photo
Kondeti Venkata Surya Siva Kumar
Corresponding author

Department of Pharmacology and Pharmaceutics, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chandramoulipuram, Chowdavaram, Guntur, Andhra Pradesh – 522019, India

Photo
Saripella Latha Sree
Co-author

Department of Pharmacology and Pharmaceutics, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chandramoulipuram, Chowdavaram, Guntur, Andhra Pradesh – 522019, India

Photo
Saripella Jaya Sree
Co-author

Department of Pharmacology and Pharmaceutics, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chandramoulipuram, Chowdavaram, Guntur, Andhra Pradesh – 522019, India

Kondeti Venkata Surya Siva Kumar, Saripella Latha Sree and Saripella Jaya Sree, Tolvaptan - Vasopressin Antagonist for Hyponatremia, Int. J. in Pharm. Sci., 2023, Vol 1, Issue 8, 1-8. https://doi.org/10.5281/zenodo.8206257

More related articles
Formulation Optimization and Evaluation of Immedia...
Shubham Balaji Palekar, Dr. S. D. Barhate, ...
Orally Dissolving Strips: A Novel Formulation for ...
Ketan Patil , Shyam Patil , Lokesh Chaudhari , Divyesh Gahivad , ...
A Comprehensive Review on Liposomes: As A Novel Drug Delivery System...
Aarti Nimse , Dr. Sachin Kale , Rutuja Giram , Ashvini Kakad, ...
Formulation & Evaluation of an Essential Oil-Based Gel for Mosquito Repellency a...
Vaibhavi Ghundare, Hardik Rakshe, Hemalata Dange, Bindu Rani Ram, Pramod Ingale, ...
A Detailed Review of FDA-Approved Drugs for Lung Cancer: Progress in Precision M...
Mayur ghughe, Vishnu Rajbhar , Nikita Negi , Uma kabra , ...
Related Articles
Phytochemicals And Health Benefits of Moringa Oleifera: A Comprehensive Review...
Subham Roy, Aditi Anand, Faizi Alam, Chayanika Goswami, ...
Method Development, Validation and Forced Degradation Study of Lasmiditan by HPL...
S. Yasotha, Dr. R. Manivannan, Dr. D. Kamalakannan, Vanmathi. R. L., Gowtham T., Praveen Kumar S., ...
Pharmacological Screening Technique: Elisa Techhnique ...
Harshwardhan Yesugade , Omkar Shelake, Shubham Salunkhe, Manoj Bachche, J. R. Kambale, Dr. Nilesh Ch...
More related articles
Orally Dissolving Strips: A Novel Formulation for Quick Drug Absorption...
Ketan Patil , Shyam Patil , Lokesh Chaudhari , Divyesh Gahivad , Mohammed Awais , Shaikh Habiburrahm...
Orally Dissolving Strips: A Novel Formulation for Quick Drug Absorption...
Ketan Patil , Shyam Patil , Lokesh Chaudhari , Divyesh Gahivad , Mohammed Awais , Shaikh Habiburrahm...